title: Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.
abstract: OBJECTIVE
  To estimate the rate of pathologic complete response (pCR) to neoadjuvant chemotherapy in BRCA1 mutation carriers according to chemotherapy regimen.
  
  
  METHODS
  From a registry of 6,903 patients, we identified 102 women who carried a BRCA1 founder mutation and who had been treated for breast cancer with neoadjuvant chemotherapy. Pathologic complete response was evaluated using standard criteria.
  
  
  RESULTS
  Twenty-four (24%) of the 102 BRCA1 mutation carriers experienced a pCR. The response rate varied widely with treatment: a pCR was observed in one (7%) of 14 women treated with cyclophosphamide, methotrexate, and fluorouracil (CMF); in two (8%) of 25 women treated with doxorubicin and docetaxel (AT); in 11 (22%) of 51 women treated with doxorubicin and cyclophosphamide (AC) or fluorouracil, doxorubicin, and cyclophosphamide (FAC), and in 10 (83%) of 12 women treated with cisplatin.
  
  
  CONCLUSIONS
  A low rate of pCR was observed in women with breast cancer and a BRCA1 mutation who were treated with AT or CMF. A high rate of pCR was seen after treatment with cisplatin. An intermediate rate of PCR was associated with AC or FAC. The relative benefits of AC and platinum therapy need to be confirmed through follow-up of this and other cohorts.
authors.affiliation: Department of Genetics andPathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
authors.forename: Tomasz
authors.initials: T
authors.lastname: Byrski
authors.forename: Jacek
authors.initials: J
authors.lastname: Gronwald
authors.forename: Tomasz
authors.initials: T
authors.lastname: Huzarski
authors.forename: Ewa
authors.initials: E
authors.lastname: Grzybowska
authors.forename: Magdalena
authors.initials: M
authors.lastname: Budryk
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Stawicka
authors.forename: Tomasz
authors.initials: T
authors.lastname: Mierzwa
authors.forename: Marek
authors.initials: M
authors.lastname: Szwiec
authors.forename: Rafal
authors.initials: R
authors.lastname: Wisniowski
authors.forename: Monika
authors.initials: M
authors.lastname: Siolek
authors.forename: Rebecca
authors.initials: R
authors.lastname: Dent
authors.forename: Jan
authors.initials: J
authors.lastname: Lubinski
authors.forename: Steven
authors.initials: S
authors.lastname: Narod
mesh_terms: D000328:Adult; D000367:Age Factors; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D019398:Genes, BRCA1; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D012042:Registries; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate